AbbVie on Pace for Largest Percent Decrease Since October 2023 — Data Talk
AbbVie, Inc. (ABBV) is currently at $172.01, down $5.32 or 3%
--Would be lowest close since Feb. 5, 2024, when it closed at $171.26
--On pace for largest percent decrease since Oct. 27, 2023, when it fell 4.32%
--Currently down four consecutive days; down 5.54% over this period
--Longest losing streak since Oct. 3, 2023, when it fell for six straight trading days
--Worst four-day stretch since the four days ending May 2, 2023, when it fell 6.29%
--Up 11% year-to-date
--Down 5.54% from its all-time closing high of $182.10 on March 28, 2024
--Up 6.47% from 52 weeks ago (April 6, 2023), when it closed at $161.55
--Down 5.54% from its 52-week closing high of $182.10 on March 28, 2024
--Up 29.81% from its 52-week closing low of $132.51 on June 28, 2023
--Traded as low as $171.71; lowest intraday level since Feb. 6, 2024, when it hit $169.77
--Down 3.17% at today's intraday low; largest intraday percent decrease since Nov. 9, 2023, when it fell as much as 4.35%
--Sixth worst performer in the S&P 500 today
All data as of 1:40:18 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 04, 2024 13:57 ET (17:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track